Amgen And Allergan Report ‘Positive’ Results On Rituximab
Executive Summary
Amgen and Allergan have announced positive top-line results from a pivotal clinical study of their rituximab biosimilar version of Roche’s blockbuster biologic Rituxan to treat patients with non-Hodgkin's lymphoma.